Phio Pharmaceuticals Corp. (NASDAQ: PHIO) will present clinical study results for its PH-762 drug candidate at the American Academy of Dermatology's Late-Breaking Research Session on March 28, 2026 in Denver, Colorado.

The presentation will highlight results from the company's Phase 1b clinical study evaluating PH-762 as a treatment for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. The study examined the safety and tolerability of intratumoral PH-762 administered before surgery.

According to the company, 22 patients completed treatment across five dose-escalation cohorts with no dose-limiting toxicities or serious adverse events reported. Phio reported a pathological response rate in cutaneous squamous cell carcinoma of approximately 65% across all dosing cohorts, including an 85% response rate in the highest-dose cohort involving 6 of 7 patients.

"Preliminary clinical evidence demonstrates that intratumoral PH-762 may provide substantial clinical benefit, with notable pathologic response, and modest mean reductions in tumor burden following treatment," said Mary Spellman, the company's acting Chief Medical Officer.

PH-762 uses Phio's INTASYL gene silencing technology designed to target the PD-1 gene. The company plans to engage with the Food and Drug Administration regarding next-stage clinical development during the second quarter of 2026.

Phio reported cash and cash equivalents projected to sustain operations into the first half of 2027. The company develops treatments using siRNA technology aimed at enhancing immune cells to target cancer cells.

The presentation is scheduled for 3:00-3:12 PM Mountain Daylight Time at the Bellco Theatre in the Colorado Convention Center.